Results of biomarker analysis from phase II trial of nivolumab in refractory biliary tract cancer.

Elaine Tan,Dae Won Kim,Jun Min Zhou,Michael J. Schell,Vincent Chung,Olatunji B. Alese,Richard D. Kim

Results of biomarker analysis from phase II trial of nivolumab in refractory biliary tract cancer.

2021

Elaine Tan
Dae Won Kim
Jun Min Zhou
Michael J. Schell
Vincent Chung
Olatunji B. Alese
Richard D. Kim

338Background: Our previous phase II study demonstrated that nivolumab provides modest but durable clinical efficacy in patients (pts) with refractory biliary tract cancer (BTC), suggesting the sig...

Keywords:

Internal medicine
Biomarker Analysis
Medicine
Nivolumab
Phases of clinical research
Gastroenterology
biliary tract cancer
Refractory
in patient
clinical efficacy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations